US Congress Senate Bill 377

---

Spectrum: Partisan Bill (Democrat 5-0)
Status: Introduced on February 7 2019 - 25% progression
Action: 2019-02-07 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]

Medicare Negotiation and Competitive Licensing Act of 2019 This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.) The CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities. Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).

Medicare Negotiation and Competitive Licensing Act of 2019

Sen. Sherrod Brown [D-OH]	Sen. Tammy Baldwin [D-WI]	Sen. Amy Klobuchar [D-MN]	Sen. Kamala Harris [D-CA]
Sen. Elizabeth Warren [D-MA]

Date	Chamber	Action
2019-02-07	Senate	Read twice and referred to the Committee on Finance.

HB1046 (Related) 2019-09-25 - Subcommittee Hearings Held.

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/senate-bill/377/all-info
Text	https://www.congress.gov/116/bills/s377/BILLS-116s377is.pdf